TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23279713

Group type: EXPERIMENTAL
Intervention: Oral training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 20339966

Group type: EXPERIMENTAL
Intervention: Ramipril (2.5-5 mg/day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Elderly patients with stable angina pectoris (SAP) (control group)
Number of subjects: 72
Study: 18489500

Group type: EXPERIMENTAL
Intervention: OAB-q questionnaire
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: OAB-q HRQL subscales
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: PPBC (patient's perception of bladder condition)
Number of subjects: 398
Study: 16310303

Group type: EXPERIMENTAL
Intervention: Cerec system [CHAIR]
Number of subjects: 10

Group type: COMPARATOR
Intervention: IPS Empress system [LAB]
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cerec system [CHAIR] and IPS Empress system [LAB]
Number of subjects: 10
Study: 12661198

Group type: EXPERIMENTAL
Intervention: Parametric adjustments to Hill-type musculo-tendon models
Number of subjects: 0
Study: 10811328

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 20 mg/kg/prednisolone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Azathioprine (AZA) 2 mg/kg/prednisolone
Number of subjects: 24
Study: 8809913

Group type: COMPARATOR
Intervention: AHA position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ERC position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MMC position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rautek's position
Number of subjects: 20
Study: 1534715

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitrendipine (20 mg)
Number of subjects: 0
Study: 6201145

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Plasma
Number of subjects: 80
Study: 31574323

Group type: EXPERIMENTAL
Intervention: Three-dimensional object version of the DCCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard two-dimensional DCCS
Number of subjects: 0
Study: 29402241

Group type: EXPERIMENTAL
Intervention: Interactive mHealth application on safe sexual health installed on smartphones
Number of subjects: 446

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Interactive mHealth application
Number of subjects: 446
Study: 27081187

Group type: EXPERIMENTAL
Intervention: Participation for Quit Assistance
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Learning about research or helping others quit
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Learning about smoking and risks
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Quit Assistance
Number of subjects: 255
Study: 24930625

Group type: EXPERIMENTAL
Intervention: Ramucirumab (10mg/kg) + Dacarbazine (1000 mg/m(2)) (Arm A)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Ramucirumab only (10mg/kg) (Arm B)
Number of subjects: 106
Study: 22881197

Group type: EXPERIMENTAL
Intervention: Camelina meal (15%)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control diet (15% canola meal)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Camelina meal (various levels)
Number of subjects: 180
Study: 20967670

Group type: EXPERIMENTAL
Intervention: Concentric warm-up exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: No prior exercise (control)
Number of subjects: 10
Study: 17654281

Group type: EXPERIMENTAL
Intervention: High-frequency words in Experiment 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-frequency words in Experiment 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-imageability words in Experiment 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-imageability words in Experiment 2
Number of subjects: 0
Study: 16299436

Group type: EXPERIMENTAL
Intervention: Statistically homogeneous results of primary randomized controlled trials (RCTs)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Large overall effect size
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Data presented as risk difference for treatment outcome
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Small effect size
Number of subjects: 120
Study: 11977877

Group type: EXPERIMENTAL
Intervention: Methacholine challenge testing
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Full pulmonary function testing (PFT)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Arterial blood gas testing
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Chest radiography (CXR)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Laboratory evaluation
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Cardiac evaluation
Number of subjects: 105
Study: 10067001

Group type: COMPARATOR
Intervention: GAD-relevant words, speech anxiety-relevant words, strongly pleasant words, and neutral valence words in the 1st experiment
Number of subjects: 122

Group type: COMPARATOR
Intervention: Threatening words in the 2nd experiment
Number of subjects: 122
Study: 8527621

Group type: EXPERIMENTAL
Intervention: Loperamide oxide 0.5 mg
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Loperamide oxide 1 mg
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 2275651

Group type: EXPERIMENTAL
Intervention: Midazolam to supplement local anaesthesia
Number of subjects: 32

Group type: COMPARATOR
Intervention: Local anaesthesia alone
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 32
Study: 109935

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy (vincristine, fluorouracil, methotrexate, and thiotepa) for 3 months after adrenalectomy-oophorectomy
Number of subjects: 31

Group type: COMPARATOR
Intervention: No chemotherapy (Control group)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Combined chemotherapy (vincristine, fluorouracil, methotrexate, and thiotepa)
Number of subjects: 31
Study: 29306475

Group type: EXPERIMENTAL
Intervention: Darapladib, 160mg daily
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 27756421

Group type: COMPARATOR
Intervention: Donepezil 10 mg QD
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: ABT-126 25 mg QD
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: ABT-126 50 mg QD
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: ABT-126 75 mg QD
Number of subjects: 438
Study: 25352616

Group type: EXPERIMENTAL
Intervention: Postural control intervention
Number of subjects: 76

Group type: COMPARATOR
Intervention: Manual stretching
Number of subjects: 76
Study: 22955245

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral smoking cessation treatment with 8 weeks of open-label nicotine patch treatment
Number of subjects: 83
Study: 20545208

Group type: EXPERIMENTAL
Intervention: Calming the liver and restraining the Yang formula
Number of subjects: 348

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 348
Study: 18375569

Group type: EXPERIMENTAL
Intervention: Oral paliperidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral paliperidone (doses > 3 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study: 16649835

Group type: EXPERIMENTAL
Intervention: Citalopram treatment for 32 weeks
Number of subjects: 30
Study: 11250997

Group type: EXPERIMENTAL
Intervention: Interactive Breast Cancer CDROM
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 180
Study: 9602961

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg twice daily for 1 week
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no cimetidine)
Number of subjects: 10
Study: 7992443

Group type: EXPERIMENTAL
Intervention: Active ionizing device
Number of subjects: 19

Group type: COMPARATOR
Intervention: Inactive placebo-device
Number of subjects: 19
Study: 2465815

Group type: EXPERIMENTAL
Intervention: Supportive care plus combination chemotherapy (cisplatin and vinblastine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive care (palliative radiation, psychosocial support, analgesics, nutritional support)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 0
Study: 8375679

Group type: EXPERIMENTAL
Intervention: Dynamic resistance strength training program (12 weeks, 3 times per week using elastic tubing)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 55
Study: 391489

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasone butyrate
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.1% hydrocortisone butyrate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study: 31270176

Group type: EXPERIMENTAL
Intervention: Active Heat-and-Moisture Exchanger (HME)
Number of subjects: 15
Study: 27786578

Group type: EXPERIMENTAL
Intervention: Oral labetalol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral extended release nifedipine
Number of subjects: 50
Study: 25246441

Group type: EXPERIMENTAL
Intervention: Customised foot orthoses
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sham foot orthoses
Number of subjects: 140
Study: 23026349

Group type: EXPERIMENTAL
Intervention: Tai Chi training for six months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Waitlist control receiving unaltered usual medical care
Number of subjects: 60
Study: 21726495

Group type: EXPERIMENTAL
Intervention: Gliclazide 80 mg with 240 ml of 20% glucose solution after a 10 h overnight fasting
Number of subjects: 18

Group type: COMPARATOR
Intervention: Test products A & B
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference product R
Number of subjects: 18
Study: 19950717

Group type: EXPERIMENTAL
Intervention: Inactivated poliomyelitis vaccine (IPV)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Oral poliomyelitis vaccine (OPV)
Number of subjects: 416
Study: 17322810

Group type: EXPERIMENTAL
Intervention: Ultrafil 3D system with .06 tapered master cone
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Ultrafil 3D system with .02 tapered master cone
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Cold lateral condensation with .06 tapered master cone
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Cold lateral condensation with .02 tapered master cone
Number of subjects: 44
Study: 15364319

Group type: EXPERIMENTAL
Intervention: Bivalirudin with provisional GP IIb/IIIa blockade
Number of subjects: 6010

Group type: COMPARATOR
Intervention: Heparin with routine GP IIb/IIIa blockade
Number of subjects: 6010

Group type: EXPERIMENTAL
Intervention: Clopidogrel pretreatment
Number of subjects: 6010
Study: 11826803

Group type: EXPERIMENTAL
Intervention: Osteoporosis prevention measures during childhood
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintaining adequate levels of calcium intake, serum vitamin D, and weightbearing physical activity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Creation of reference data for bone mineralization
Number of subjects: 0
Study: 9661556

Group type: EXPERIMENTAL
Intervention: Bupivacaine with 2 micrograms/kg clonidine for ICB
Number of subjects: 36

Group type: COMPARATOR
Intervention: Bupivacaine with saline for ICB and IM injection of saline (Control group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bupivacaine with saline for ICB and IM injection of 2 micrograms/kg clonidine (IM group)
Number of subjects: 36
Study: 7662226

Group type: EXPERIMENTAL
Intervention: 240 mg verapamil
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 10 mg enalapril
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 240 mg verapamil + 10 mg enalapril
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: 120 mg verapamil + 10 mg enalapril
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 186
Study: 2569239

Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 67

Group type: COMPARATOR
Intervention: Loprazolam 1 mg
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Preferred treatment (either triazolam or loprazolam)
Number of subjects: 67
Study: 772175

Group type: EXPERIMENTAL
Intervention: Bromocriptine (26 mg daily for 12 weeks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 30569761

Group type: EXPERIMENTAL
Intervention: Block Periodization (BLOCK)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Daily Undulating Periodization (DUP)
Number of subjects: 47
Study: 28209488

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (n=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 80
Study: 26468834

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied with GaAlAs, 830 nm wavelength, power of 40 mW, energy of 8.4 J/cm2 dose per spot, applied in 8 treatment sessions at 48-hour intervals
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no laser therapy)
Number of subjects: 9
Study: 23481125

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (250 mg of standardized soy extract corresponding to isoflavone 100 mg/day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 20959525

Group type: EXPERIMENTAL
Intervention: Aclidinium 200 µg
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Aclidinium 800 µg
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 19946430

Group type: EXPERIMENTAL
Intervention: Ultrasonographic screening for AAA
Number of subjects: 4
Study: 17048062

Group type: EXPERIMENTAL
Intervention: Milk basic protein (MBP) 40 mg per day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 14732661

Group type: COMPARATOR
Intervention: Skin self‐examination without photography
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Skin self‐examination with photography
Number of subjects: 50
Study: 12025949

Group type: EXPERIMENTAL
Intervention: Perindopril 4 mg daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9669245

Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 2141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2141
Study: 7809577

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.4 mg/kg body weight as an intravenous bolus followed by continuous infusion of 0.4 mg/kg/h for 6 hours)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Indomethacin + light hypoxia
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Indomethacin + hypercapnia
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Moderate hypoxia (FiO2 13%)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 3292590

Group type: EXPERIMENTAL
Intervention: Regulated-breathing method (treatment)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 32
Study: 30223773

Group type: EXPERIMENTAL
Intervention: Repositioning the R‐DLT into the left main bronchus (Group L)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Repositioning the R‐DLT into the right main bronchus (Group R)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Quality of lung collapse during one‐lung ventilation (Group L)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bronchial injuries (Group R)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bronchial injuries (Group L)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vocal cord injuries (Group R)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vocal cord injuries (Group L)
Number of subjects: 60
Study: 27982270

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Pyridostigmine
Number of subjects: 16
Study: 25529060

Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID) patients at ICU discharge
Number of subjects: 107

Group type: COMPARATOR
Intervention: Non-ID patients at ICU discharge
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Patients at D28
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Patients at M6
Number of subjects: 107
Study: 23782092

Group type: EXPERIMENTAL
Intervention: Board game
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional lecture
Number of subjects: 120
Study: 20728932

Group type: EXPERIMENTAL
Intervention: HEV 239 vaccine (30 microg of purified recombinant hepatitis E antigen adsorbed to 0.8 mg aluminium hydroxide suspended in 0.5 mL buffered saline)
Number of subjects: 56302

Group type: COMPARATOR
Intervention: Placebo (hepatitis B vaccine)
Number of subjects: 56302
Study: 18279190

Group type: EXPERIMENTAL
Intervention: Hemospan (200 to 1000 mL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ringer's lactate (control group)
Number of subjects: 30
Study: 15834928

Group type: EXPERIMENTAL
Intervention: AC+D (neoadjuvant chemotherapy with docetaxel)
Number of subjects: 121

Group type: COMPARATOR
Intervention: AC (neoadjuvant chemotherapy without docetaxel)
Number of subjects: 121
Study: 14501008

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10507279

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study: 7795834

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction of dietary sodium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of weight loss and reduction of dietary sodium
Number of subjects: 0
Study: 1940817

Group type: EXPERIMENTAL
Intervention: Postcard reminder intervention
Number of subjects: 1068

Group type: COMPARATOR
Intervention: No postcard reminder (Control)
Number of subjects: 1068

Group type: EXPERIMENTAL
Intervention: Postcard reminder intervention (aged 65 and over)
Number of subjects: 1068

Group type: COMPARATOR
Intervention: No postcard reminder (Control, aged 65 and over)
Number of subjects: 1068
Study: 7457492

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Tracheotomy
Number of subjects: 150
Study: 31277537

Group type: EXPERIMENTAL
Intervention: Dihuang Decoction (DHD), taken orally, one dose each time, twice a week for one year
Number of subjects: 72

Group type: COMPARATOR
Intervention: Alendronate sodium 70 mg orally once a week for one year
Number of subjects: 72

Group type: COMPARATOR
Intervention: Comparison of BMD, serum beta-CTX, and serum SOST between DHD and alendronate groups after treatment
Number of subjects: 72
Study: 28378600

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training plus non-invasive ventilatory support
Number of subjects: 46

Group type: COMPARATOR
Intervention: Combined aerobic and resistance training alone
Number of subjects: 46
Study: 26804967

Group type: EXPERIMENTAL
Intervention: Formulation 2 (dual route/dual release fixed dose combination tablet)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Formulation 1 (testosterone solution for sublingual administration and sildenafil tablet)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formulation 2
Number of subjects: 12

Group type: COMPARATOR
Intervention: Formulation 1
Number of subjects: 12
Study: 25005572

Group type: EXPERIMENTAL
Intervention: Post-distribution door-to-door visits with educational messages and assistance in hang-up of nets.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: One or two additional door-to-door visits.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention visits).
Number of subjects: 0
Study: 23477707

Group type: EXPERIMENTAL
Intervention: Ticlopidine plus Ginkgo Biloba extract (250mg ticlopidine plus 80mg Ginkgo Biloba extract twice daily)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Ticlopidine (250mg twice daily)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Clopidogrel (75mg daily)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 127
Study: 20864061

Group type: COMPARATOR
Intervention: Jaw lift maneuver (Group J)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tongue traction using a padded artery forceps (Group T)
Number of subjects: 100
Study: 17588604

Group type: EXPERIMENTAL
Intervention: Propranolol (one-day dose)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 15889241

Group type: EXPERIMENTAL
Intervention: i.v. citalopram
Number of subjects: 12
Study: 14529054

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 440 microg
Number of subjects: 262

Group type: COMPARATOR
Intervention: Budesonide (BUD) 400 microg
Number of subjects: 262

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study: 10357038

Group type: EXPERIMENTAL
Intervention: Thrice weekly ECT
Number of subjects: 40

Group type: COMPARATOR
Intervention: Once weekly ECT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Post-seizure FD at first ECT
Number of subjects: 40
Study: 8647503

Group type: EXPERIMENTAL
Intervention: Fetal membranes that have ruptured 12 hours before onset of labor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 0
Study: 8348280

Group type: EXPERIMENTAL
Intervention: OM-8980 24 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: OM-8980 48 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: OM-8980 6 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: OM-8980
Number of subjects: 60
Study: 3745529

Group type: EXPERIMENTAL
Intervention: Oral acyclovir 800 mg twice a day for 5 days
Number of subjects: 157

Group type: COMPARATOR
Intervention: Standard dosage of oral acyclovir 200 mg five times a day
Number of subjects: 157
Study: 30168209

Group type: EXPERIMENTAL
Intervention: New X-ray system (AlluraClarity FD20/10, Philips Healthcare)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Reference X-ray modality (Allura Xper FD10, Philips Healthcare)
Number of subjects: 122
Study: 26791931

Group type: EXPERIMENTAL
Intervention: 29 MHz micro-ultrasound system with PRI-MUS protocol
Number of subjects: 2000